AL
Therapeutic Areas
Neuren Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Trofinetide (NNZ-2566) / DAYBUE™ | Rett Syndrome | Approved |
| Trofinetide (NNZ-2566) | Fragile X Syndrome | Phase 2 |
| NNZ-2591 | Phelan-McDermid Syndrome | Phase 2 |
Leadership Team at Neuren Pharmaceuticals
JP
Jon Pilcher
Chief Executive Officer (CEO)
RT
Richard Treagus
Executive Director and Company Secretary
TF
Tony Fifer
Non-Executive Chairman
DS
Dr. Stephen Clarke
Non-Executive Director
DM
Dr. Michael D. Snape
Chief Development Officer (CDO) and Company Founder
DJ
Dr. Juha P. Tolonen
Chief Medical Officer (CMO)